BHC Valeant Pharmaceuticals: חובות לטווח קצר של החברה

Bausch Health Companies (BHC) competes in the dermatology and gastroenterology segments, seeking to reduce debt through asset sales. This chart on GURU.Markets reflects liquidity dynamics for the short-term debt portfolio, with the indicator holding around 0.00. Management aims to unlock business value by optimizing the corporate structure. The holding's resilience is based on a wide range of ophthalmological and cosmetic products.

Steady demand for Bausch Health Companies (BHC) ophthalmology solutions ensures a consistent cash flow to service obligations. By analyzing short-term borrowings due within one year, an investor assesses the aggregate of loans and bonds maturing within twelve months, which allows for the determination of liquidity risk and the impact of current payments on free cash flow and the holding's overall financial stability.